S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%

Investing

INDV logo Indivior : INDV

Price Target $60 ↑56.6%
›

INDV

Stock Data

$38.82

Change up

$0.15 (0.39%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - SPECIALTY & GENERIC

Indivior Plc specializes in creating prescription drugs aimed at treating opioid dependence and related disorders. Its main products include SUBLOCADE, a subcutaneous injection, and SUBOXONE and SUBUTEX, both sublingual tablets designed to manage opioid use disorder, addiction, and schizophrenia. With a presence in around 40 countries, Indivior focuses on improving the lives of those struggling with these conditions. Founded in 2014 and based in North Chesterfield, Virginia, the company also collaborates with Addex Therapeutics Ltd to expand its treatment offerings.

Latest Activity

INDVIndivior Pharmaceuticals, Inc.
Q2 2026
EPS
$1.15
est $0.92+24.8%
Revenue
$343M
est $308M+11.5%

Indivior torched consensus estimates with a 24.76% EPS beat and raised full-year guidance as SUBLOCADE, its long-acting injectable buprenorphine treatment, posted 21% revenue growth and a record 32,816 new patient starts. The opioid-use-disorder drug is now pulling 76% of the U.S. long-acting buprenorphine market, signaling durable demand and a potential inflection point ahead of the company's pending all-stock merger with Supernus.

Quarterly EPS — reported vs estimate
Read more

All Indivior Articles

1 Article